​READ OUR CLiNiCAL REPORTS:

​

The real‐world application of T‐cell receptor constant beta‐1 chain antibody assay in cutaneous T‐cell lymphoma

British Journal of Haematology, 2025

​

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy

Haematologica, 2025

​

Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma

Blood Advances, 2024

​

Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged≥ 55

Transplantation and Cellular Therapy, 2022

​

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Transplantation and Cellular Therapy, 2022

​

Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy

British Journal of Haematology, 2020

​

Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy

The Oncologist, 2020

​

Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study

Biology of Blood and Marrow Transplantation, 2020

​

Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma

The Oncologist, 2020

​

Allogeneic haploidentical blood or marrow transplantation with post-transplantation cyclophosphamide in chronic lymphocytic leukemia

Biology of Blood and Marrow Transplantation, 2020

​